Company Description

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines.

Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Psyence Biomedical Ltd.

Country	Canada
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	12
CEO	Jody Aufrichtig

Contact Details

Address: 121 Richmond Street West, Penthouse Suite 1300 Toronto, ON M5H 2K1 Canada
Phone	416-477-1708
Website	psyencebiomed.com

Stock Details

Ticker Symbol	PBM
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	1985062
CUSIP Number	74449F407
ISIN Number	CA74449F4078
SIC Code	2834

Key Executives

Name	Position
Jody Aufrichtig	Co-Founder, Executive Chairman and Chief Executive Officer
Warwick Ron Corden-Lloyd	Chief Financial Officer and Director
Dr. Neil Maresky M.D.	Global Head of Clinical Development
Taryn Vos	General Counsel

Latest SEC Filings

Date	Type	Title
Jun 22, 2026	20-F	Annual and transition report of foreign private issuers
Jun 10, 2026	SCHEDULE 13G/A	Filing
Jun 5, 2026	6-K	Report of foreign issuer
Jun 3, 2026	SCHEDULE 13D	Filing
Apr 23, 2026	6-K	Report of foreign issuer
Apr 20, 2026	6-K	Report of foreign issuer
Apr 17, 2026	6-K	Report of foreign issuer
Apr 15, 2026	6-K	Report of foreign issuer
Mar 2, 2026	6-K	Report of foreign issuer
Feb 20, 2026	6-K	Report of foreign issuer

View All SEC Filings